SOLV·Solventum Corporation
$86.34
+1.03 (+1.21%)
Overnight$86.30-0.04 (-0.05%)
High
$86.49
Open
$86.01
Market Cap
14.69B
52W High
$94.16
Low
$83.29
P. Close
$86.34
P/E
10.24
52W Low
$62.38
Fwd P/E
11.91
DailyIQ Est.
$97.15
Inst. Ownership
38.3%
Short Interest
2.88%
Days to Cover
5.4
Technical Score (1D)
50
NEUTRAL
News Sentiment
66
BULLISH
SOLV scores 50 on the 1D technical view with a NEUTRAL signal and mixed momentum. Price action is in a neutral range - the market is coiling, and neither side has been willing to push to a definitive break. Sentiment at 66 is diverging from the flat technical backdrop, removing sentiment as a directional catalyst for now. Consolidations like this are often a sign that the market is waiting for new information before committing capital in either direction. The range between $82.85 and $89.75 is well-defined. When this kind of compression resolves - particularly if it resolves with a gap or range-expansion bar - the follow-through tends to be more sustained than a typical breakout because of the energy that builds during the quiet phase.
Coiled setups like this are as much about time as they are about price - the longer SOLV compresses between $82.85 and $89.75 without a catalyst, the more the eventual move tends to compensate. Watching for a volume spike on the actual break, rather than trying to anticipate direction from the shape of the range, has historically been the more reliable approach.
SOLV|Analyst Targets
SOLV|Analyst Targets
LOW TARGET
$71 -17.7%
2 analysts
MEAN TARGET
$95 +9.7%
12 analysts
HIGH TARGET
$113 +30.9%
9 analysts
PRICE RANGE
$71.00 - $113.00
SB / B / H / S / SS
6/7/8/1/1
DAILYIQ EST.
$97.15 (+12.6%)
SOLV|Company Info
SOLV|Company Info
Sector
Healthcare
Industry
Medical Instruments & Supplies
Exchange
NYQ
Country
United States
Website
Symbol
SOLV
Description
Solventum Corporation is a healthcare solutions provider focused on meeting crucial needs within the medical industry, both domestically and internationally. The company's core business revolves around three primary segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg division delivers a wide array of products, from advanced wound care and surgical supplies to sterilization assurance and temperature management tools. Solventum's Dental Solutions segment offers a comprehensive portfolio of dental and orthodontic products, while the Health Information Systems segment provides software and services designed to improve healthcare system efficiency. Solventum distributes its offerings through a multi-channel approach, including direct sales, distribution networks, and e-commerce platforms.
SOLV|Insider Trading
SOLV|Insider Trading
Bought (1Y)
0 shares
$0
Sold (1Y)
52,418 shares
$4.3M
Hanson Bryan CChief Executive Officer
Hanson Bryan CChief Executive Officer
Hanson Bryan CChief Executive Officer
Zieselman Neil CraigSVP, Controller & CAO
Wilson Darryl L.-
SOLV|Fundamentals
SOLV|Fundamentals
Neutral / mixed
Overall: Neutral
Revenue growing year over year
Positive net margin
Positive operating cash flow
Gross Margin
53.5%
Gross profit as a share of revenue: what's left after the direct cost of producing what's sold.
Net Margin
18.7%
Net income as a share of revenue: what's left for shareholders after every expense.
Revenue CAGR
0.8%
Compound annual growth rate of revenue across the fiscal years on file.
Current Ratio
1.23x
Current assets divided by current liabilities: the ability to cover obligations due within a year. Above 1.5x is comfortable, below 1x is a warning sign.
Debt / Equity
1.00x
Total interest-bearing debt divided by shareholder equity: how leveraged the balance sheet is.
Return on Equity
30.8%
Net income divided by shareholder equity: how efficiently the company turns equity capital into profit.
SOLV|Earnings Snapshot
SOLV|Earnings Snapshot
Earnings Summary
Solventum Corporation operates as a healthcare solutions provider, delivering Medsurg, Dental Solutions, and Health Information Systems products that span surgical supplies, dental devices, and software services to improve system efficiency. The company competes in the broader medical instruments and supplies sector, where demand is driven by hospital procurement cycles and aging populations. In the most recent two quarters, Solventum posted EPS of $1.69 in Q2 2025 and $1.57 in Q4 2025, both above analyst expectations of $1.45 and $1.53 respectively, while revenue rose to $2.161 billion and $1.998 billion, respectively, reflecting a modest YoY increase of roughly 4% in Q4 2025 versus the prior year. The company has consistently beaten EPS estimates in the last four quarters, with Q1 2026 EPS of $1.48 surpassing the $1.35 forecast, and Q2 2026 EPS of $2.55 exceeding the $1.94 estimate, indicating a strong earnings trajectory despite revenue growth slowing slightly in Q4 2025. Historically, Solventum has maintained a steady YoY revenue growth path, with a 12% increase in Q4 2024 and a 9% rise in Q1 2025, while EPS has trended upward, underscoring a pattern of solid profitability even when revenue growth decelerates. Recent news highlights a 12% YoY revenue jump in Q4 2024 driven by stronger surgical equipment sales and an AI‑enabled robotics focus, suggesting that the company’s transformation initiatives are beginning to pay off and could shift the revenue mix toward higher‑margin products. The company’s continued R&D investment signals a commitment to sustaining competitive positioning, but any delays or cost overruns could impact near‑term profitability.
EPS
EstBeatMiss
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $1.35 | - | - |
| Q2'26 | $1.94 | $2.55 | +31.2% |
| Q1'26 | $1.35 | $1.48 | +9.3% |
| Q4'25 | $1.53 | $1.57 | +2.9% |
| Q3'25 | $1.43 | $1.50 | +4.7% |
| Q2'25 | $1.45 | $1.69 | +16.3% |
Revenue
EstBeatMiss
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $2.0B | - | - |
| Q2'26 | $2.2B | $2.2B | +0.5% |
| Q1'26 | $2.0B | $2.0B | +1.8% |
| Q4'25 | $2.0B | $2.0B | -0.1% |
| Q3'25 | - | $2.1B | - |
| Q2'25 | - | $2.2B | - |
SOLV|Monthly Returns
SOLV|Monthly Returns
Market Data
SOLV Stock Snapshot
$86.30−$0.04 (0.0%)
- Market cap
- 14.69B
- P/E ratio
- 10.2
- Day range
- $83.29 – $86.49
- News sentiment
- 66/100 · Bullish
- Analyst target
- $94.69 (+9.7%)
- Consensus
- Hold · 23 analysts
52-week range+38.3% off low · -8.3% from high
$62.38$94.16
Price $86.30 DailyIQ Est. $97.15
Neither side has the upper hand on SOLV right now, and its momentum ranks near the middle of DailyIQ's universe. In Healthcare, names this size usually take direction from sector flows before company-level news.
Behaviour On Record
What SOLV's own history says about today's numbers
- Realized volatility (21d)
- 15.7% 2nd pct
- vs 200-day average
- +10.6%
- Up days (1y)
- 47%
Solventum Corporation is currently running 15.7% annualised volatility over the last 21 sessions. Measured against SOLV's own 2 years of daily returns rather than a market-wide average, that is the 2nd percentile — unusually subdued by its own history, against a typical reading of 30.1%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
Price sits +10.6% from its 200-day moving average. Against every other day in its history, that gap ranks at the 71st percentile — a somewhat wider gap than its own norm. Over the past year SOLV closed higher on 47% of sessions, and it is currently 1 session into a rising streak.
Overnight risk is measurable too: SOLV has opened more than 2% away from the prior close in 31 of 639 sessions (4.9% of the time), with the largest gaps running +4.5% and -6.6%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
Across the last 3 dated reports on file, SOLV moved an average of 4.7% in the session after earnings, closing higher 1 of those 3 times, with a median move of -1.1% and a largest of -7.4%.
All figures computed from 640 daily closes between 2024-03-26 and 2026-10-13, split-adjusted, recomputed daily. Percentiles are against SOLV's own 3-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of SOLV's sector?
Solventum Corporation sits in the Health Care sector, currently ranked 5th of 12 GICS sectors by relative-strength rotation score (improving).
- Sector rank
- #5 of 12
- Sector state
- Improving
- Sector rotation score
- 64
Analyst Rating Changes
Are analysts turning bullish or bearish on SOLV?
BTIG most recently reiterated its rating on Solventum Corporation to Buy on Sep 14, 2026 with a price target of $95. Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.
- Latest action
- BTIG — Buy
- 90-day upgrades
- 1
- 90-day downgrades
- 0
- Net rating momentum
- +1
Peers & ETF holders
SOLV peers & ETF holders
Medical Instruments & SuppliesMarket cap · today
News Sentiment Analysis
Sentiment gathered from recent headlines
66/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
10+ articles
Technical Analysis
Real-time indicators across multiple timeframes
50
NEUTRAL
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Institutional & Hedge Fund Ownership
25 tracked managers · $5.01B combined position · 13 adding, 11 trimming, 1 unchanged (latest 13F filings)
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| Vanguard Group Inc | ▼ Sell | 17,026,542 | 10.00% | $1.35B | 2026-01-29 |
| BlackRock, Inc. | ▼ Sell | 9,761,863 | 5.73% | $753.13M | 2026-08-07 |
| Trian Fund Management, L.P. | • Hold | 8,236,753 | 4.84% | $635.47M | 2026-08-12 |
| Davis Selected Advisers | ▼ Sell | 6,307,729 | 3.71% | $486.69M | 2026-08-11 |
| Geode Capital Management, LLC | ▲ Buy | 4,910,624 | 2.88% | $378.31M | 2026-08-12 |
| Invesco Ltd. | ▼ Sell | 3,309,915 | 1.94% | $255.36M | 2026-08-14 |
| FMR LLC (Fidelity) | ▲ Buy | 2,079,141 | 1.22% | $160.41M | 2026-08-13 |
| Norges Bank | ▼ Sell | 1,713,676 | 1.01% | $132.21M | 2026-08-12 |
| Morgan Stanley | ▼ Sell | 1,533,215 | 0.90% | $118.29M | 2026-08-13 |
| Northern Trust Corp | ▼ Sell | 1,387,579 | 0.82% | $107.05M | 2026-08-13 |
| Bank of America Corp | ▼ Sell | 1,291,866 | 0.76% | $99.67M | 2026-08-14 |
| Millennium Management LLC | ▲ Buy | 1,199,940 | 0.70% | $92.58M | 2026-08-14 |
| AQR Capital Management LLC | ▲ Buy | 1,082,100 | 0.64% | $83.48M | 2026-08-14 |
| Goldman Sachs Group Inc | ▲ Buy | 956,447 | 0.56% | $73.79M | 2026-08-14 |
| Gotham Asset Management, LLC | ▲ Buy | 763,416 | 0.45% | $58.90M | 2026-08-14 |
| JPMorgan Chase & Co | ▲ Buy | 649,037 | 0.38% | $51.32M | 2026-08-12 |
| D. E. Shaw & Co., Inc. | ▲ Buy | 526,392 | 0.31% | $40.61M | 2026-08-14 |
| Marshall Wace, LLP | ▲ Buy | 351,518 | 0.21% | $27.12M | 2026-08-13 |
| Wells Fargo & Company | ▼ Sell | 266,106 | 0.16% | $20.53M | 2026-08-14 |
| Balyasny Asset Management L.P. | ▼ Sell | 247,812 | 0.15% | $19.12M | 2026-08-14 |
| Squarepoint Ops LLC | ▲ Buy | 243,128 | 0.14% | $18.76M | 2026-08-14 |
| Bridgewater Associates, LP | ▲ Buy | 177,921 | 0.10% | $13.73M | 2026-08-14 |
| Citigroup Inc | ▲ Buy | 158,963 | 0.09% | $12.26M | 2026-08-03 |
| AllianceBernstein L.P. | ▼ Sell | 155,292 | 0.09% | $10.14M | 2026-08-14 |
| Susquehanna International Group, LLP | ▲ Buy | 119,340 | 0.07% | $9.21M | 2026-08-14 |
Q2 2026 flow:2.75M sh bought ($212.12M)2.13M sh sold ($164.34M)net +613.7K sh (+$47.78M)
Congressional Trading Activity
7 disclosed trades · ~$80.5K est. traded value · 2 buys, 5 sells
| Member | Chamber | State | Type | Amount | Traded | Filed |
|---|---|---|---|---|---|---|
| Alan Armstrong | Senate | OK | ▲ Buy | $1K - $15K | 2026-03-27 | 2026-07-21 |
| James French Hill | House | AR02 | ▼ Sell | $15K - $50K | 2025-12-31 | 2026-01-23 |
| Ron Wyden | Senate | OR | ▼ Sell | $1K - $15K | 2025-02-06 | 2025-02-21 |
| Julie Johnson | House | TX32 | ▼ Sell | $1K - $15K | 2025-01-15 | 2025-02-12 |
| Gary Peters | Senate | MI | ▼ Sell | $1K - $15K | 2024-05-14 | 2024-05-23 |
| Tommy Tuberville | Senate | AL | ▼ Sell | $1K - $15K | 2024-05-03 | 2026-08-05 |
| Tommy Tuberville | Senate | AL | ▲ Buy | $1K - $15K | 2024-05-03 | 2024-06-14 |